Document Detail


Multicenter clinical trial of thrombolytic therapy in 1,406 patients with acute myocardial infarction. Collaborative Group of Clinical Trial for Urokinase Therapy.
MedLine Citation:
PMID:  9772414     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: To investigate the clinical efficacy and safety of intravenous thrombolytic therapy of Urokinase Tech-Pool (UKTP) in acute myocardial infarction (AMI). METHODS: The data were collected from the 148 participating hospitals from November, 1994 to April, 1996. A total of 1,406 patients with AMI were analyzed to evaluate the clinical efficacy, side effects and mortality of UKTP. The patency of the infarct-related artery (IRA) was evaluated in 124 patients by coronary artery angiography (CAG) 90 minutes after the onset of UKTP infusion. RESULTS: The reperfusion rate in IRA was 73.5% by clinical standards. The patency rate was 72.6% by CAG. The total mortality during the first 5 weeks was 7.8% (109/1,406). The rate of minor bleeding was 10.2% (143/1,406), of major bleeding 0.43% (6/1,406) and of intracranial hemorrhage 0.50% (7/1,406). In elderly patients (> 75 years old), UKTP was as effective and safe as in younger patients (< 65 years old). Late thrombolytic therapy with UKTP (> 6 hours after the onset of symptom) was still effective. The appropriate dosage of UKTP might be 150 million units of infusion within 30 minutes. CONCLUSION: UKTP is an effective, reliable and safe agent in the thrombolytic therapy of AMI.
Authors:
D Hu; Z Xu
Related Documents :
2345834 - The applicability of the results of streamlined trials to clinical practice.
15028324 - Impact of emergency medicine faculty on door to thrombolytic time.
21370304 - Fetal heart ventricle mass obtained by stic acquisition combined with inversion mode an...
23339744 - Thyroid hormone levels within reference range are associated with heart rate, cardiac s...
15529564 - Permanent ventricular pacing via a low posterolateral cardiac vein in a patient with a ...
17010794 - Thrombus aspiration reduces microvascular obstruction after primary coronary interventi...
Publication Detail:
Type:  Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study    
Journal Detail:
Title:  Chinese medical journal     Volume:  110     ISSN:  0366-6999     ISO Abbreviation:  Chin. Med. J.     Publication Date:  1997 Nov 
Date Detail:
Created Date:  1998-10-27     Completed Date:  1998-10-27     Revised Date:  2008-11-21    
Medline Journal Info:
Nlm Unique ID:  7513795     Medline TA:  Chin Med J (Engl)     Country:  CHINA    
Other Details:
Languages:  eng     Pagination:  839-42     Citation Subset:  IM    
Affiliation:
Heart Center, Beijing Red Cross Chaoyang Hospital, China.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Female
Humans
Male
Middle Aged
Myocardial Infarction / drug therapy*,  mortality
Thrombolytic Therapy*
Time Factors
Urokinase-Type Plasminogen Activator / administration & dosage,  adverse effects,  therapeutic use*
Chemical
Reg. No./Substance:
EC 3.4.21.73/Urokinase-Type Plasminogen Activator

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Oral captopril versus placebo among 14,962 patients with suspected acute myocardial infarction: a mu...
Next Document:  Effects of removing circulatory tumor necrosis factor by immunoadsorption on experimental endotoxin ...